Evidence map›Paper›PMID 40646051›Full record

ArticleScientific reports2025

Machine learning based characterization of high risk carriers of HTLV-1-associated myelopathy (HAM).

Md Ishtiak Rashid, Junya Sunagawa, Akari Matsuki, Asami Yamada, Toshiki Watanabe, Masako Iwanaga, Ki-Ryang Koh, Takafumi Shichijo, Masao Matsuoka, Jun-Ichirou Yasunaga and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Md Ishtiak RashidGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Junya SunagawaGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Akari MatsukiQuantitative Life Sciences, The Abdus Salam International Centre for Theoretical Physics (ICTP), Trieste, Italy.
Asami YamadaDepartment of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Toshiki WatanabeDepartment of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Masako IwanagaDepartment of Clinical Epidemiology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Ki-Ryang KohDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Takafumi ShichijoDepartment of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Masao MatsuokaDepartment of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Jun-Ichirou YasunagaDepartment of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. jyasunag@kumamoto-u.ac.jp.
Shinji NakaokaFaculty of Advanced Life Science, Hokkaido University, Sapporo, Japan. snakaoka@sci.hokudai.ac.jp.

Funding

Japan Agency for Medical Research and Development 21fk0108088h0003Japan Science and Technology Agency JPMJCR23J4Moonshot Research and Development Program JPMJMS2021
6 · The paper itself

Abstract

HTLV-1-associated myelopathy (HAM) develops in a part of HTLV-1-infected individuals while most of the individuals remain asymptomatic. This complicates the identification of HTLV-1 carriers at elevated risk. In this study, we integrated HTLV-1 proviral load and antibody titers against Tax, Env, Gag p15, p19, and p24 proteins in a machine learning (ML) framework to identify and characterize high-risk individuals likely to develop HAM. We stratified asymptomatic carrier samples employing an anomaly detection model. We further developed and validated classifier models capable of distinguishing three clinical subgroups, carrier, ATL, and HAM for assessing the anomaly carrier samples as unseen test data. With most anomaly carrier samples (~ 76.47%) predicted as HAM, further statistical and interpretative analysis revealed the 'HAM-like' characteristics of the anomaly carrier samples indicating elevated risk. Additionally, significant heterogeneity in immune response was observed among other asymptomatic carriers. As an exploratory, hypothesis-generating study, our findings are preliminary and aim to propose potential biomarkers and computational strategies that warrant validation in future longitudinal investigations. Our machine learning-based approach offers a novel and insightful tool for identifying and evaluating high-risk characteristics for HAM, providing a holistic view of the complex immune dynamics of asymptomatic carriers of HTLV-1.

Indexed as

Carrier StateHTLV-I InfectionsHuman T-lymphotropic virus 1Machine LearningParaparesis, Tropical SpasticAdultFemaleHumansMaleMiddle AgedRisk FactorsViral Load

Identifiers

PMID40646051
PMCPMC12254224

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.